Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Alberto R. [Tc(CO)3]+ chemistry: a promising new concept for SPET? For. Eur J Nucl Med Mol Imaging 2003; 30:1299–1302.CrossRefPubMed
2.
Welch MJ, Lewis JS. [Tc(CO)3]+ chemistry: a promising new concept for SPECT? Against. Eur J Nucl Med Mol Imaging 2003; 30:1302–1304.CrossRefPubMed
3.
Guo W, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999; 40:1563–1569.PubMed
4.
Liu S, Harris AR, Williams NE, Edwards DS. 99mTc-labeling of a hydrazinonicotinamide-conjugated LTB(4) receptor antagonist useful for imaging infection and inflammation. Bioconjug Chem 2002; 13:881–886.CrossRefPubMed
5.
Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2002; 29:1529–1542.CrossRefPubMed
6.
Egli A, Alberto R, Tannahill L, Schibli R, Abram U, Schaffland A, Waibel R, Tourwé D, Jeannin L, Iterbeke K, Schubiger PA. Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999; 40:1913–1917.PubMed
7.
Ballinger JR. The effect of carrier on technetium-99m radiopharmaceuticals. Q J Nucl Med 2002; 46:224–232.PubMed
8.
Maisey M. Is PET the future of nuclear medicine? For. Eur J Nucl Med Mol Imaging 2003; 30:1045–1046.CrossRefPubMed
9.
Bailey DL. Is PET the future of nuclear medicine? Against. Eur J Nucl Med Mol Imaging 2003; 30:1046–1049.
10.
Alberto R, Schibli R, Egli A, Schubiger AP. A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998; 120:7987–7988.
11.
Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, Bläuenstein P, Tourwé D, García-Garayoa E, Bischof-Delaloye A. Radiolabeled neurotensin analog. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003; 44:1649–1654.
Metadata
Title
Re: Controversies—[Tc(CO)3]+ chemistry: a promising new concept for SPET?
Authors
James R. Ballinger
Margaret S. Cooper
Stephen J. Mather
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1374-z

Other articles of this Issue 2/2004

European Journal of Nuclear Medicine and Molecular Imaging 2/2004 Go to the issue

Book reviews

Nuclear medicine in the management of inflammatory and infectious diseases

Letter to the Editor

Reply

Blue pages

EANM Learning Course on Clinical PET. General Information

Editorial

Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Original Article

Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma

Original Article

Requirements for clinical PET: comparisons within Europe